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Background: Mitochondria are more than just the powerhouse of cells; they dictate if a cell dies or survives.
Mitochondria are dynamic organelles that constantly undergo fusion and fission in response to environmental
conditions. We showed previously that mitochondria of cells in a low oxygen environment (hypoxia) hyperfuse to
form enlarged or highly interconnected networks with enhanced metabolic efficacy and resistance to apoptosis.
Modifications to the appearance and metabolic capacity of mitochondria have been reported in cancer. However,
the precise mechanisms regulating mitochondrial dynamics and metabolism in cancer are unknown. Since hypoxia
plays a role in the generation of these abnormal mitochondria, we questioned if it modulates mitochondrial
function. The mitochondrial outer-membrane voltage-dependent anion channel 1 (VDAC1) is at center stage in
regulating metabolism and apoptosis. We demonstrated previously that VDAC1 was post-translationally C-terminal
cleaved not only in various hypoxic cancer cells but also in tumor tissues of patients with lung adenocarcinomas.
Cells with enlarged mitochondria and cleaved VDAC1 were also more resistant to chemotherapy-stimulated cell
death than normoxic cancer cells.
Results: Transcriptome analysis of mouse embryonic fibroblasts (MEF) knocked out for Vdac1 highlighted alterations
in not only cancer and inflammatory pathways but also in the activation of the hypoxia-inducible factor-1 (HIF-1)
signaling pathway in normoxia. HIF-1α was stable in normoxia due to accumulation of reactive oxygen species
(ROS), which decreased respiration and glycolysis and maintained basal apoptosis. However, in hypoxia, activation
of extracellular signal-regulated kinase (ERK) in combination with maintenance of respiration and increased glycolysis
counterbalanced the deleterious effects of enhanced ROS, thereby allowing Vdac1−/− MEF to proliferate better
than wild-type MEF in hypoxia. Allografts of RAS-transformed Vdac1−/− MEF exhibited stabilization of both HIF-1α
and HIF-2α, blood vessel destabilization, and a strong inflammatory response. Moreover, expression of Cdkn2a, a
HIF-1-target and tumor suppressor gene, was markedly decreased. Consequently, RAS-transformed Vdac1−/− MEF
tumors grew faster than wild-type MEF tumors.
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Conclusions: Metabolic reprogramming in cancer cells may be regulated by VDAC1 through vascular destabilization
and inflammation. These findings provide new perspectives into the understanding of VDAC1 in the function of
mitochondria not only in cancer but also in inflammatory diseases.Background
While the Warburg effect, or aerobic glycolysis, is consid-
ered to be primarily responsible for the metabolic repro-
gramming of cancer cells [1], mitochondrial respiration
remains functional. However, it is not clear how mito-
chondria impact on proliferation or transformation of can-
cer cells, but as the «powerhouse» of cells, any change in
metabolism can strongly influence the survival of the can-
cerous cell. Mitochondria are not only crucial in metabolic
reprogramming; they also play an important role in deliv-
ering the message of cell death i.e., apoptosis. When the
mitochondrial membrane potential (Δψm) is lost, mito-
chondria lose the integrity of their outer membrane, ATP
synthesis is stopped, and proteins such as cytochrome C
activate a cascade of caspases, ensuring certain death of
the cell [2, 3].
The voltage-dependent anion channel (VDAC) is a
major protein of the mitochondrial outer membrane that
functions at the intersection of metabolism and apop-
tosis. The mammalian mitochondrial porin family in-
cludes three isoforms: VDAC1, VDAC2, and VDAC3 [4].
However, their expression levels differ according to the
type of tissue, as do their physiological function. Mice
lacking Vdac1 or Vdac3 are viable, whereas mice lacking
Vdac2 are not. While heterozygous Vdac1+/− mice ap-
pear to have no obvious phenotype, when mated, they
showed a reduced number of homozygous deficient mice
when compared to the expected Mendelian ratio [5].
Only 40 % of the expected number of Vdac1−/− mice
survived, suggesting partial lethality, the reason for
which has not yet been elucidated. VDAC1 is a pore that
regulates the passage of molecules, including NADH,
ATP/ADP, citrate, succinate, glutamate, pyruvate, and
even glucose, as well as Mg2+, Ca2+, Cl−, K+, and Na+
ions [4]. It regulates the mitochondrial phenotype, apop-
tosis, and glycolysis through binding to hexokinase I/II
(HKI/II), the first enzyme of the glycolytic pathway.
Binding of HK to VDAC is a crucial event that coordi-
nates mitochondrial ATP generation, cytoplasmic glyco-
lytic flux, and possibly cytochrome C release. Moreover,
HKI/II are upregulated by hypoxia-inducible factors
(HIFs), the key transcription factors that direct the cell
response to hypoxia, a condition in which tumors are in-
adequately oxygenated [6]. It is well known that the hyp-
oxic nature of tumors is associated with poor clinical
outcome, as hypoxia confers resistance to radio- and
chemotherapy.The role of VDAC1 in cancer has not been extensively
investigated [7, 8, 4]. We recently reported the presence
in tumor cells of a novel hypoxia-induced form of
VDAC1 lacking the C-terminus (VDAC1-ΔC) [7, 9].
This new form was produced after long-term exposure
to hypoxia. Cells expressing VDAC1-ΔC produced more
ATP and were more resistant to stimulated apoptosis
than cells expressing only full length VDAC1. In hyp-
oxia, the level of full length VDAC1 decreased by about
at least 50 % while the level of VDAC1-ΔC conversly in-
creased by about 50 %. We hypothesized that knockout
of VDAC1 in hypoxia would have a substantial impact
on cell proliferation, oxidative and glycolytic metabol-
ism, as well as apoptosis in hypoxic cells.
Herein, we characterized the cellular and molecular
phenotype of Vdac1-deficient mouse embryonic fibro-
blasts (MEF) in normoxia or hypoxia. We report that
VDAC1 participates in apoptosis and oxidative phosphor-
ylation via reactive oxygen species (ROS) production,
which modulates proliferation. We report connection to
the Raf/MEK/ERK signaling pathway that counterbalances
the deleterious effects of ROS in hypoxia. Finally, we show
that knockout of Vdac1 in MEF expressing oncogenic
RAS potentiates tumor development in mice by pro-
moting metabolic reprogramming, accelerating vascular
destabilization and inflammation.
Methods
Cell culture, transfection, and animals
MEF cells were grown in Dulbecco’s modified eagle’s
medium (DMEM) (Gibco-BRL) supplemented with 10 %
fetal bovine serum with penicillin G (50 U/ml) and
streptomycin sulfate (50 μg/ml). An INVIVO2 200 an-
aerobic workstation (Ruskinn Technology Biotrace Inter-
national Plc) set at 1 % oxygen, 94 % nitrogen, and 5 %
carbon dioxide was used for hypoxic conditions. MEF
were transformed with the pBabe-RASV12 vector, and
puromycin-resistant cells were collected. Animal proce-
dures were approved by the Animal Care and Use Com-
mittee of the Unité Mixte de Service 006 of Toulouse
(approval number 13-U1037-JES-08).
Electron microscopy
Cells were fixed in situ with 1.6 % glutaraldehyde in
0.1 M phosphate buffer at room temperature (RT) and
stored overnight at 4 °C. Samples were rinsed in the same
buffer and then postfixed with 1 % osmium tetroxide and
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1 h at RT to enhance the staining of cytoplasmic mem-
branes. Cells were rinsed with distilled water, embedded in
epoxy resin, sectioned, and examined with a Philips CM12
transmission electron microscope equipped with an
Olympus SIS CCD camera. The area of the mitochondria
of cells was calculated as an ellipse (0.785ab; n.2, 50 mito-
chondria per experiment; mean ± SD).
ATP determination
MEF (Wt and Vdac1−/−) and RAS MEF (Wt and Vdac1−/−)
were incubated in hypoxia for 72 h and then lysed. Quanti-
fication of ATP was done using a luciferin/luciferase-based
assay (Cell Titer Glo kit, Promega) according to the manu-
facturer’s instructions, and results are expressed as relative
luminescence units (RLU). Each condition was tested eight
times, and the entire experiment was done twice.
Lactate measurement
The lactate concentration in the supernatant of cells
incubated either in normoxia or hypoxia for 48 h was
determined by an enzyme-based assay using 900 μM β-
NAD (BioChemika) and 175 μg/ml L-lactate dehydro-
genase (BioChemika), and 100 μg/ml glutamate-pyruvate
transaminase (Roche) were diluted in a sodium carbon-
ate (620 mM)-L-gultamate (79 mM) buffer adjusted to
pH 10. Lithium lactate was used as a standard. Measure-
ment was done with a microplate reader after incubation
for 30 min at 37 °C. For each condition, the protein con-
centration was determined to express the lactate con-
centration as mmole/μg protein.
Respirometry and extracellular acidification
The cellular oxygen consumption rate (OCR) and extra-
cellular acidification rate (ECAR) were obtained using a
Seahorse XF96 extracellular flux analyzer from Seahorse
Bioscience (North Billerica, MA, USA). The final con-
centrations of the agents are given in the legends. Experi-
ments were performed according to the manufacturer’s
instructions. Protein standardization was performed after
each experiment, with no noticeable differences in protein
concentration and cell phenotype.
Determination of glutamate production
Glutamate concentrations were measured in media su-
pernatants using a Ysi 2300 STAT Plus analyzer (YSI Life
Sciences). Measurements were done in triplicate, and
the experiment was repeated two times.
Caspase activation
Quantification of the caspase 3/7 activity was done using
a luciferin/luciferase-based assay (Caspase-Glo 3/7 kit,
Promega) according to the manufacturer’s instructions.
Each condition was performed eight times, and theentire experiment was done three times. Significant dif-
ferences are based on the Student’s t test (p < 0.005).
STS was added 4 h prior to assay for caspase 3/7
activity.
Flow cytometry and ROS measurement
For measuring intracellular cytosolic ROS levels, cells
were cultured in hypoxia or normoxia for 48 h. Cells
were then treated with oxidation sensitive DCF-DA (a
final concentration of 10 μM) in culture medium for
30 min at 37 °C. After trypsination, the fluorescence of
DCF in cells was measured using a fluorescence-
activated cell sorter (BD FACSCalibur, analyzer). Mito-
chondrial H2O2 production was determined using
Amplex UltraRed as described [10] but with a Xenius
XC Safas spectrofluorimeter (Monaco) at λexcitation =
560 nm, λemision = 590 nm. Whole digitonin perme-
abilized cells were used instead of isolated mitochondria,
as described [11]. The assay was performed with 0.6 mg
protein/ml of each cell type suspended in KHEP buffer
without BSA (120 mM KCl, 2.5 mM MgCl2, 1 mM
EGTA, 5 mM HEPES pH 7.2 at 37 °C) together with
5 U/ml horseradish peroxidase, 25 U/ml superoxide dis-
mutase, and 50 μM Amplex UltraRed. The reaction was
monitored and digitonin (final 10 μg/ml), then potassium
succinate (final 5 mM), and then antimycin A (final
2 mM) were added successively. The results are expressed
as the mean slope ratio of antimycin A/succinate.
Immunoblotting
Cells were lysed in 1.5x SDS buffer and the protein con-
centration determined using the BCA assay. 40 μg of pro-
tein of whole cell extracts was resolved by SDS-PAGE and
transferred onto a PVDF membrane (Millipore). Mem-
branes were blocked in 5 % non-fat milk in TN buffer
(50 mM Tris–HCl pH 7.4, 150 mM NaCl) and incubated
in the presence of the primary and then secondary anti-
bodies in 5 % non-fat milk in TN buffer.
The Bak antibody was purchased from Abcam, Bid
and tBid from R&D Systems, Bax and Bcl-XL from Santa
Cruz, Bcl-2 from Novus, and Mcl-1 from Sigma. Rat
anti-mouse CD31 (MEC 13.3) was from BD Bioscience
(San Diego, CA). VDAC1 antibody (ab15895) was pur-
chased from Abcam. Rabbit polyclonal anti-HIF-1α anti-
body (antiserum 2087) was produced and characterized
in our laboratory [12]. ECL signals were normalized to
either β-tubulin or ARD1 [13]. After washing in TN buf-
fer containing 1 % Triton-X100 and then in TN buffer,
immunoreactive bands were visualized with the ECL sys-
tem (Amersham Biosciences).
Microarray experiments
MEF were incubated in normoxia or hypoxia for 72 h
(1 % O2) and then lysed prior to RNA isolation. RNA
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ser 2100 (Agilent Technologies) (RIN above 9). RNA
samples were then labeled with Cy3 dye using the low
RNA input QuickAmp kit (Agilent) as recommended by
the supplier. Labeled cRNA probe (825 ng) was hybridized
on 8x60K high density SurePrint G3 gene expression
mouse microarrays. The experimental data are deposited
on the NCBI Gene Expression Omnibus (GEO) under the
series record number GSE63247 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE63247). Normalization of
microarray data was performed using the Limma pack-
age available from Bioconductor (http://www.bioconductor.
org). Inter-slide normalization was performed using quan-
tile methods. Means of ratios from all comparisons were
calculated and a B test analysis using paired analysis was
performed. Differentially expressed genes were selected
based on an adjusted p value below 0.01 and a log2 (fold
change) >1. Data were analyzed for enrichment in bio-
logical themes (diseases and functions, canonical pathways,
upstream analysis) using Ingenuity Pathway Analysis soft-
ware (http://www.ingenuity.com/).
Statistics
All values are the means ± SEM. Statistical analysis were
performed using the Student’s t test as provided by
Microsoft Excel. The p values are indicated. All categor-
ical data used numbers and percentages. Quantitative
data were presented using the median and range or
mean. Differences between groups were evaluated using
the chi-square test for categorical variables and the Stu-
dent’s t test for continuous variables. Analyses were
performed using SPSS 16.0 statistical software (SPSS
Inc., Chicago, Ill). All statistical tests were two-sided,
and p values <0.05 indicated statistical significance,
whereas p values between 0.05 and 0.10 indicated a
statistical tendency (Additional file 1).
The online version of the article contains a data supplement
Additional file 2: Table S1, Additional file 3: Table S2,
Additional file 4: Table S3, Additional file 5: Table S4,
Additional file 6: Figure S1 and Additional file 7: Figure
S2 show detailed data related to the microarray analysis.
Additional file 8: Figure S3 shows expression of COX4-
2. Additional file 9: Figure S4 shows the ROS status.
Additional file 10: Figure S5 shows expression of GPX7
and the effect of ebselen. Additional file 11: Figure S6
shows changes in metabolic pathways. Additional file 12:
Figure S7 shows data on glucose and glutamine catabolism.
Additional file 13: Figure S8 shows the level of apoptosis.
Additional file 14: Figure S9 shows electron micrograph
and immunoblotting data related to autophagy. Additional
file 15: Figure S11 shows data on vascularization of the
RAS-MEF tumor tissue. Additional file 16: Figure S12
shows the immunohistochemistry to VEGF of tumorsections. Additional file 17: Figure S13 shows an in silico
analysis of the Vdac1 gene in cancer.
Results
High-throughput gene expression profiling of wild-type
and Vdac1−/− mouse embryonic fibroblasts
We confirmed that VDAC-ΔC was produced in hypoxia
in wild-type (Wt) MEF [14] and that the VDAC1 protein
was not expressed in Vdac1−/− MEF [5] (Fig. 1a). We
then analyzed the transcriptome of Wt and Vdac1−/−
MEF in normoxia or hypoxia using a mouse whole gen-
ome microarray. Only RNA transcripts showing an ad-
justed p value <0.01 and an absolute log2 (fold change) >1
in at least one differential expression analysis were consid-
ered. Figure 1b and c recapitulates the number of genes
differentially expressed when comparing the RNA tran-
script expression of Vdac1−/− vs Wt MEF and the re-
sponse of both cells lines to hypoxia, respectively. The
data showed alteration in the gene expression profile of
Vdac1−/− MEF compared to Wt MEF in both normoxia
and hypoxia (Fig. 1d, e). Analysis of the hypoxic response
identified changes between the two cell lines (Fig. 1c, d).
To understand the functional relevance of differentially
expressed up- and down-regulated genes in Vdac1−/−
compared to Wt MEF, the microarray data were analyzed
with Ingenuity Pathway AnalysisTM (IPATM) software
using the same cut-offs for both cells lines. The Vdac1 de-
ficiency, highlighted terms associated with «Diseases and
functions» (Additional file 2: Table S1A), «Canonical path-
ways» (Additional file 2: Table S1B), and «Upstream regu-
lators» (Additional file 2: Table S1C) in both normoxia
and hypoxia. These results pointed to alterations in pro-
grams controlling cancer through metabolic pathways
modulating HIF-1, cell death and survival, as well as cell
proliferation and motility. Analysis revealed alterations in
the hypoxic response of Vdac1−/− MEF, including a lack of
inhibition of cell proliferation, an increased oxidative
stress response, and p53 activation (Additional file 3: Table
S2). The «HIF-1α» signaling pathway both in normoxia
(Fig. 1f) and hypoxia (Additional file 2: Figure S1) and the
«Upstream regulators» «HIF-1α» were highlighted in
Vdac1−/− MEF (Additional file 2: Tables S1B-C and Add-
itional file 16: S2B-C). The HIF-1α protein was detectable
in normoxia in Vdac1−/− MEF and increased in hypoxia to
a level higher than that of Wt MEF in hypoxia, when
equivalent numbers of cells were seeded (Fig. 1g). HIF-2α
was also present at a higher level in Vdac1−/− MEF, but
only in hypoxia.
Vdac1−/− MEF proliferated faster than Wt MEF in hypoxia
through activation of the ERK1/2 pathway
The IPATM analysis highlighted cell proliferation and mi-
gration in Vdac1−/− MEF in hypoxia with increased HIF-
1 signaling (Additional file 3: Table S2A). Wt MEF
Fig. 1 Characterization of wild-type (Wt) and VDAC1 null (Vdac1−/−) mouse embryonic fibroblasts (MEF) in normoxia (Nx) and hypoxia 1 % O2
(Hx). a Wt and Vdac1−/− MEF were incubated in Nx or Hx for 72 h and cell lysates were analyzed by immunoblotting for VDAC. β-tubulin was
used as a loading control. mRNA was extracted from Wt or Vdac1−/− cells after 72 h in Nx or Hx, and mRNA profiles were determined using
pan-genomic microarrays. b Venn diagram depicting the numbers of genes significantly modulated between Wt vs Vdac1−/− MEF in normoxia
(Nx) or hypoxia (Hx). c Venn diagram depicting the numbers of genes significantly modulated between Hx and Nx in Wt or Vdac1−/− MEF.
d Heatmap comparing normalized log2 gene intensities of the top-ranked differentially expressed genes (1925 probes) for Wt and Vdac1−/−MEF
incubated in Nx or Hx (n = 2). The distance was measured using the Manhattan distance on the matrix of the log2 (intensity) and classification
was performed using a complete agglomeration method. e Correlation between the change in the mRNA level between Wt and Vdac1−/−MEF in
normoxia and hypoxia. The determination coefficient (R2) was calculated using log2 fold changes from top modulated genes. f HIF-1α signaling pathway
in normoxia in Vdac1−/− MEF vs Wt MEF. Red and green color codes for up- and down-regulation, respectively. g Wt (+) and Vdac1−/− (−) MEF were
incubated in Nx or Hx for 72 h and cell lysates were analyzed by immunoblotting for HIF-1α and HIF-2α. β-tubulin was used as a loading control
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oxia (Fig. 2a). To examine if reintroduction of Vdac1
into Vdac1−/− MEF could reverse the effect on growth,we transiently transfected a pFlag-VDAC1 vector that
has previously been shown to lead to expression of
VDAC1 that integrates correctly into the mitochondrial
Fig. 2 Characterization of the growth of Wt and Vdac1−/− MEF. a Both cell lines were seeded at the same density and incubated in Nx or Hx for
the indicated number of days. The mean ± SEM is representative of four independent experiments carried out in duplicate. A p < 0.0002 shows
significant difference from normoxia for the Vdac1−/− MEF. b Immunoblotting of HeLa cells transfected with pFlag-VDAC1. c Immunoblotting and
proliferation assay of MEF tranfected with pFlag-VDAC1 d Relative migration of Wt and Vdac1−/− MEF in Nx as evaluated with a xCELLigence
system. The mean ± SEM is representative of two independent experiments carried out in quadruplicate. e Characterization of the growth of Wt
and Vdac1−/− MEF incubated in Nx or in Hx for 3 days in the absence or presence of an inhibitor of MEK (U0126, 10 μM). The mean ± SEM is
representative of two independent experiments carried out in duplicate. f Wt (+) and Vdac1−/− (−) cells were incubated in Nx or Hx in the
absence or presence of an inhibitor of MEK (U0126). Cell lysates were analyzed by immunoblotting for phospho-ERK (P-ERK), total ERK (ERK) and
β-tubulin as a loading control. g Immunofluorescence of P-ERK in Wt and Vdac1−/− MEF in Hx. h Wt (+) and Vdac1−/− (−) MEF were incubated in
Nx or Hx for 72 h and cell lysates were analyzed by immunoblotting for DUSP6. ARD1 was used as a loading control. (i) Immunoblotting of Wt
MEF and Hif-1α−/− MEF for DUSP6
Brahimi-Horn et al. Cancer & Metabolism  (2015) 3:8 Page 6 of 18membrane [15]. However, since MEF do not transfect eas-
ily, we first tested the vector on HeLa cells and confirmed
both expression of VDAC1 and its post-translational
cleavage in hypoxia (Fig. 2b), as we described [14, 9]. Weobserved that Vdac1−/− MEF transfected with pFlag-
VDAC1 proliferated slightly faster than empty vector
transfected Vdac1−/− MEF (Fig. 2c), suggesting that des-
pite the low level of transfection, the absence of VDAC1
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MEF did not grow well in normoxia, but in hypoxia,
showed similar growth to Wt MEF in normoxia. Vdac1−/−
MEF also migrated three times faster than Wt MEF in
normoxia (Fig. 2d). To investigate whether the extracellu-
lar signal-regulated kinases 1 and 2 (ERK1/2) signaling
pathway was involved, we cultured the cells in normoxia
or hypoxia with or without U0126, a selective inhibitor of
the intracellular Raf/MEK/ERK signaling pathway (Fig. 2e).
In Vdac1−/− MEF, U0126 had no effect on proliferation in
normoxia, whereas proliferation in hypoxia was abolished
with U0126 suggesting that the ERK1/2 pathway restored
normal growth in hypoxia in Vdac1−/− MEF. Expression
of phospho-ERK1/2 was enhanced in hypoxia in Vdac1−/−
MEF compared to Wt MEF (Fig. 2e). P-ERK was predom-
inantly localized in the cytoplasm of Wt MEF in hypoxia
(Fig. 2g). However, active ERK targeted focal adhesion
complexes in Vdac1−/− MEF in hypoxia (Fig. 2g). The dual
specificity phosphatase DUSP6, a mitogen-activated pro-
tein kinase phosphatases that dephosphorylates ERK, was
highlighted in the IPATM analysis (Additional file 4: Table
S3). A decrease in DUPS6 was observed in Wt MEF ex-
posed to hypoxia and Vdac1−/−MEF in normoxia (Fig. 2h).
This decrease in expression was dependent on HIF-1 since
the level of expression was the same in Hif-1−/− MEF in
normoxia or hypoxia (Fig. 2i). These results suggest that
ERK activation allows cells to proliferate better in hypoxia
through inactivation of DUSP6, but only in cells lacking
Vdac1.
Vdac1−/− MEF showed alterations in mitochondrial
respiration
As the IPATM analysis identified in hypoxic Vdac1−/−
MEF defects in expression of mRNAs implicated in
mitochondrial respiration (Additional file 7: Figure S2),
including complexes I, III, IV, and V, we hypothesized
that these defects could generate ROS, which could then
stabilize HIF-1α [16-18]. Mitochondria of Wt MEF in
normoxia appeared as a tubular network with normal
cristae (Fig. 3a), whereas hypoxic Wt MEF showed en-
larged mitochondria with a modified organization of
cristae, as reported [14]. The mitochondria of Vdac1−/−
MEF were enlarged, but in both normoxia and hypoxia.
In addition, hypoxic mitochondria of Vdac1−/− MEF
showed two different populations of mitochondria. One
(around 50 %; data not shown) exhibited enlarged mito-
chondria with a high number of cristae, as for tissues
with a high energy demand [19], while the other popula-
tion had the same morphology as normoxic mitochon-
dria of Vdac1−/− MEF. These results suggested that
Vdac1−/− MEF had a higher rate of respiration in hyp-
oxia than in normoxia, possibly due to more cristae,
which could promote proliferation. We quantified mito-
chondrial respiration with the Seahorse XF by measuringthe OCR. Table 1 summarizes the mitochondrial coup-
ling and respiratory control of MEF, as previously de-
scribed [20]. Basal respiration (a) of normoxic Vdac1−/−
MEF was lower than in Wt MEF (p < 0.005). In hypoxia,
the basal respiration of Wt MEF was substantially de-
creased (80 %) while that of Vdac1−/− MEF was reduced
by only 35 %. In normoxia and hypoxia, Wt and Vdac1−/−
MEF had a similar rate of proton leak (b), suggesting that
mitochondria are not damaged, consistent with the
morphology of the mitochondria. The rate of mitochon-
drial ATP synthesis (c) was also lower in Vdac1−/− MEF in
normoxia; however, although the ATP turnover was
strongly inhibited in both cell lines in hypoxia, the ATP
turnover of Vdac1−/− MEF remained two-fold higher than
that of Wt MEF. In addition, maximal respiration (d) was
lower in Vdac1−/− MEF in normoxia, but was greater or
equal to that of Wt MEF in hypoxia. The coupling effi-
ciency (c/a) was twofold lower in hypoxia than in nor-
moxia in Wt and Vdac1−/− MEF. The respiratory control
ratio (d/b) was systematically decreased in Vdac1−/− MEF.
These results confirmed that: (i) normoxic mitochondria
of Vdac1−/− MEF exhibited substantial defects in respira-
tory control and that (ii) hypoxic mitochondria of Vdac1
−/− MEF were more efficient than hypoxic Wt MEF. How-
ever, the spare respiratory capacity (d-a) indicated that the
hypoxic mitochondria had reached their bioenergetic
limit. To explain the abundance of cristae and higher res-
piration in hypoxia in Vdac1−/− MEF, we investigated the
expression of cytochrome oxidase (COX). The level of
COX4-1, was slightly decreased in hypoxia in both cell
lines (data not shown), whereas COX4-2 showed a marked
increase in hypoxia in both cell lines (Fig. 3b), as described
[21]. A higher level of COX4-2 and COX7A1 (more dots)
in Vdac1−/− MEF in hypoxia than in Wt MEF was de-
tected (Fig. 3b, Additional file 8: Figure S3A). Blockade of
COX4-2 expression and of proliferation of Vdac1−/− MEF
in hypoxia in the presence of PD184352, a specific in-
hibitor of MEK, suggested that COX4-2 could regulate
proliferation in hypoxia through the activation of ERK
(Additional file 8: Figure S3B). However, while silencing
of COX4-2 and COX7A1 with siRNA diminished sub-
stantially the respective mRNA levels, only silencing of
COX7A1 decreased proliferation in Vdac1−/− MEF with-
out modifying apoptosis (data not shown).
Blockade of complex I with rotenone in Wt MEF
markedly decreased basal respiration, suggesting a nor-
mal complex I activity in normoxia (Fig. 3c). Inhibition
with rotenone did not affect complex I activity in hyp-
oxia as it is known that its activity is already reduced in
hypoxia [22]. However, rotenone did not modify the
OCR of Vdac1−/− MEF, which suggests that the complex
I activity was already diminished. We then quantified
the levels of ROS (Fig. 3d). We found a strong correl-
ation between the inactivation of complex I and ROS
Fig. 3 ROS production by Wt and Vdac1−/− MEF. a Representative electron micrographs of mitochondria of Wt and Vdac1−/− MEF incubated in
normoxia (Nx) or hypoxia 1 % O2 (Hx) for 72 h. b Immunofluorescence to COX4-2 and COX7A1 in Wt and Vdac1
−/− MEF in Hx for 72 h. c Respiratory
control of Wt and Vdac1−/− MEF. Oxygen Consumption Rate (OCR) was measured in real time with a Seahorse XF bioenergetic system for Wt and
Vdac1−/− MEF in Nx or Hx. ΔOCR was calculated from at least four measurements before and after treatment with rotenone at 1 μM. d Quantitative
measurement of ROS production was done by staining with the fluorescent probe 2', 7'-dichlorofluorescin diacetate (DCFH-DA) followed by flow
cytometry. These graphs are representative of four different experiments; p< 0.02, significant difference to Wt MEF in normoxia (Nx). e Wt and
Vdac1−/− MEF seeded at the same density were incubated in Nx for 3 days in the presence of N-acetyl-L-cysteine (NAC, up to 1 mM). Mean ± SEM
is representative of two independent experiments carried out in duplicate. f Wt and Vdac1−/− MEF were incubated in Hx for 72 h in the absence (−)
or presence (+) of NAC (1 mM) and cell lysates were analyzed by immunoblotting for P-ERK. ARD1 was used as a loading control. g Wt (+) and
Vdac1−/− (−) MEF were incubated in Nx for 24 h in the absence (−NAC) or presence (+NAC) of NAC (1 mM) and cell lysates were analyzed by
immunoblotting for HIF-1α. ARD1 was used as a loading control. h Wt and Vdac1−/− MEF were incubated in Nx for 3 days in the presence of H2O2
(up to 100 μM). Mean ± SEM is representative of two independent experiments carried out in duplicate. i Wt (+) and Vdac1−/− (−) MEF were
incubated in Nx or Hx for 72 h and cell lysates were analyzed by immunoblotting to GPX7. ARD1 was the loading control
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UltraRed assay for mitochondrial production of H2O2,
Vdac1−/− MEF mitochondria produced more H2O2 thandid the Wt MEF (Additional file 9: Figure S4A). N-
acetyl-L-cysteine restored proliferation of Vdac1−/− MEF
in normoxia to a similar level to that of Wt MEF
Table 1 Respiratory control of Wt and Vdac1−/− MEF
Nx Hx
Wt MEF Vdac1−/− MEF Wt MEF Vdac1−/− MEF
(a) Basal respiration 20.52 ± 2.5 16.19 ± 1.8 4.5 ± 0.52 10.4 ± 2.41
(b) Oligomycin-insensitve respiration (leak) 5.96 ± 0.9 5.04 ± 0.9 2.4 ± 0.27 7.1 ± 2.73
(c) Oligomycin-sensitive (ATP turnover) respiration 14.56 ± 1.6 11.16 ± 0.8 1.8 ± 0.70 3.2 ± 0.95
(d) Maximal respiration in the presence of FCCP 29.21 ± 3.2 19.29 ± 1.7 5.4 ± 1.19 6.0 ± 0.29
(c/a) Coupling efficiency 0.71 ± 0.02 0.71 ± 0.01 0.4 ± 0.12 0.3 ± 0.13
(d/b) Respiratory control ratio 4.91 ± 0.2 3.95 ± 0.4 2.3 ± 0.71 0.8 ± 0.44
(d-a) Spare respiratory capacity 8.19 ± 1.2 3.10 ± 0.1 1.3 ± 0.50 −5.4 ± 2.83
The oxygen consumption rate (OCR) was measured in real time with a Seahorse XF bioenergetic system for Wt and Vdac1−/−MEF in Nx or Hx. The average OCR
was calculated from at least four measurements during treatment with each compound (oligomycin, FCCP, rotenone/antimycin A) at a 1 μM final concentration.
(a) represents basal respiration, (b) oligomycin-insensitive respiration, (c) oligomycin-sensitive respiration, and (d) maximal respiration in the presence of FCCP. The
graph shows how to define a, b, c, and d. The mean ± SEM is representative of six independent experiments carried out in quadruplicate
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creased HIF-1α in normoxia (Fig. 3g). Addition of
hydrogen peroxide to Wt MEF decreased proliferation
to a level similar to that of Vdac1−/− MEF (Fig. 3h).
The expression of enzymes involved in upstream or
downstream transformation of H2O2 including superoxide
dismutase 3 (Sod3) and glutathione peroxidase 7 (Gpx7)
were tightly regulated in Vdac1−/− MEF (Additional file 5:
Table S4). However, SOD1, SOD2, and SOD3 showed no
difference in expression in normoxia (Additional file 10:
Figure S5B) or hypoxia (data not shown) in Wt MEF com-
pared to Vdac1−/− MEF. GPX7, which detoxifies hydro-
peroxide substrates, was absent in Vdac1−/− MEF in both
normoxia and hypoxia (Fig. 3i, Additional file 10: Figure
S5A). Moreover, ebselen, a mimetic of GPX [23], did
not modify HIF-1α stability (Additional file 10: Figure
S5B). It decreased slightly the proliferation of Wt MEF,
but not Vdac1−/− MEF (Additional file 10: Figure S5C)
and increased slightly the viability of Vdac1−/− MEF
(Additional file 10: Figure S5D), suggesting a putative
protection against ROS in these cells.
These results showed that the accumulation of ROS in
Vdac1−/− MEF, probably due to down-regulation of
GPX7 and the stabilization of HIF-1α, participate in the
blockade of proliferation in normoxia. However, inhypoxia, activation of P-ERK and induced expression of
COX4-2 and COX7A1 compensated for the reduced
mitochondrial complex I activity in Vdac1−/− MEF.
Vdac1−/− MEF were more glycolytic in hypoxia
IPATM analysis revealed that metabolism was minim-
ally modified in Vdac1−/− MEF compared to Wt MEF
(Additional file 11: Figure S6). Nonetheless, hypoxic in-
duction of HKII was maintained in both cell lines, but the
basal amount of HKII in normoxia was lower in Vdac1−/−
MEF (Fig. 4a). We used the Seahorse XF to quantify gly-
colysis by measuring the ECAR, which primarily reflects
lactate. Addition of oligomycin, which blocks mitochon-
drial ATP production, showed that the glycolytic capacity
of Vdac1−/− MEF was more than twofold lower than that
of Wt MEF in normoxia (0.94 vs 2.34, respectively)
(Fig. 4b). However, this ratio changed in hypoxia since (i)
the basal level of glycolysis (1.75 vs 1.42) and (ii) the max-
imum capacity (1.45 vs 1.3) of Vdac1−/− MEF was greater
than that of Wt MEF (Fig. 4c). Relative to normoxia, both
lactate and ATP production were increased in Vdac1−/−
and Wt MEF in hypoxia (Fig. 4d, e). Vdac1−/− MEF were
less sensitive to blockade of respiration (oligomycin or
metformin) (Fig. 4f). As Wt MEF were extremely sensitive
to the absence of glutamine (almost 100 % cell death in
Fig. 4 Metabolic characteristics of Wt and Vdac1−/− MEF incubated in normoxia (Nx) or hypoxia 1 % O2 (Hx). a Wt (+) and Vdac1
−/− (−) MEF were
incubated in Nx or Hx for 72 h and cell lysates were analyzed by immunoblotting for HIF-1α and HKII. β-tubulin was used as a loading control.
The extracellular acidification rate (ECAR) in b Nx or c Hx of Wt and Vdac1−/− MEF was evaluated with a Seahorse XF bioenergetic system. Cells
were deprived of glucose for 1 h, then glucose (Glu 10 mM) and oligomycin (Oligo 1 μM) were injected at the indicated times. d After 3 days of
culture, cells were lysed in Assay Buffer with sonication. The amount of lactate was quantified in cell extracts. The mean ± SEM is representative of
three independent experiments carried out in duplicate. A p < 0.001 and p < 0.005 show significant differences. e ATP production of Wt and Vdac1−/−
MEF in Nx or Hx for 72 h. The mean ± SEM is representative of three independent experiments carried out in duplicate. A p < 0.0005 and
p < 0.00005 show significant differences. f Wt and Vdac1−/− MEF were cultured for 2 days in Nx or Hx in the presence of oligomycin (Oligo,
1 μM), metformin (−Metf), and without glutamine (−Gluta), in the presence of dialyzed serum. The cell number was measured on a Beckman Coulter
apparatus (squares). The percentage cell mortality was measured by trypan blue exclusion (black dots). The mean ± SEM is representative of
two independent experiments carried out in duplicate. A p < 0.01, p < 0.001, and p < 0.005 show significant differences
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was about 32.3 % in normoxia and 38.1 % in hypoxia, sug-
gesting an important role of glutamine, which is metabo-
lized to glutamate in mitochondria, in Vdac1−/− MEF. In
the presence of 2-deoxy-D-glucose, a glucose analog that
inhibits glycolysis, or in the absence of glucose, Vdac1−/−
and Wt MEF showed similar survival (Additional file 12:
Figure S7A). Finally, Vdac1−/− MEF produced little or no
glutamate in both normoxia and hypoxia compared to Wt
MEF (Additional file 12: Figure S7B). These results
confirm that the Vdac1−/− MEF grew better in hypoxia, by
maintaining respiration and promoting glycolysis.
Vdac1−/− MEF showed a higher level of apoptosis than Wt
MEF
Since “cell death of cancer cells” was highlighted in
Vdac1−/− MEF (Additional file 2: Table S1A) in the IPATM
analysis, we investigated whether the lack of Vdac1 trig-
gered apoptosis. While Wt MEF exhibited little apoptosis,
basal apoptosis was persistent in normoxia (15 %) and
hypoxia (20 %) in Vdac1−/− MEF (Fig. 5a). The basal level
of apoptosis was evaluated as 10 % of the nuclei of
Vdac1−/− MEF exhibiting blebbing in normoxia (Fig. 5b).
Moreover, no cytochrome C release was observed for Wt
MEF in normoxia, whereas Vdac1−/− MEF showed release
of cytochrome C in parallel to nuclear fragmentation
(Additional file 13: Figure S8). The expression of Bak, Bax,
and Mcl1 was similar in both cell lines and under both con-
ditions (Fig. 5c). However, the expression of Bcl-XL and Bcl-
2, two anti-apoptotic members of the Bcl-2 family, was
found to be reduced in Vdac1−/− MEF, consistent with the
basal apoptosis of these cells. In addition, Wt MEF incubated
with the apoptotic stimulus staurosporine (STS) remained
unaffected in both normoxia and hypoxia (Fig. 5d). However,
Vdac1−/− MEF were sensitive to STS in both conditions. We
further confirmed that Vdac1−/−MEF were sensitive to stim-
ulated apoptosis and were also more sensitive to chemother-
apy with doxorubicin and bleomycin than Wt MEF (Fig. 5e).
No differences were observed for cisplatin. We also con-
firmed the protective effect of hypoxia in response to irradi-
ation in Wt MEF (Fig. 5f) and found that Vdac1−/− MEF in
normoxia exhibited a level of radioresistance similar to that
of Wt MEF in hypoxia. Moreover, Vdac1−/− MEF showed
more radioresistance in hypoxia than Wt MEF. Finally, as
autophagy was also highlighted in Vdac1−/− MEF by IPATM
analysis (Additional file 3: Table S2A), we examined its in-
duction in Vdac1−/− MEF. We observed a higher back-
ground level of autophagy in Vdac1−/− MEF compared to
Wt MEF (Additional file 14: Figure S9A-B).
Vdac1−/− RASV12-transformed MEF form inflammatory
tumors that grow faster than Wt tumors
Wt and Vdac1−/− RAS-transformed MEF showed similar
expression of RAS (Fig. 6a), proliferation (Additional file18: Figure S10A), type of morphology (Additional file 18:
Figure S10B), rate of migration (Additional file 18:
Figure S10C), level of glycolysis (Additional file 18:
Figure S10D), and respiration (Additional file 18: Figure
S10E) as non-transformed MEF. However, while the Wt
RAS and Vdac1−/− RAS MEF showed the same relative
resistance to irradiation as previously observed (Fig. 5f ),
the basal level of resistance of transformed cells was
much higher than that of non-transformed cells
(Additional file 18: Figure S10F). Both Wt RAS or
Vdac1−/− RAS MEF plated in soft agar acquired the abil-
ity to grow under anchorage-independent conditions
(Additional file 18: Figure S10G). Consistent with this,
Vdac1−/− RAS MEF more rapidly formed tumors in
nod-scid mice than Wt RAS MEF (Fig. 6b). Most of the
tumors derived from Vdac1−/− RAS MEF reached a size
of 1 cm3 within 27 days of injection, whereas Wt RAS
MEF-derived tumors reached this size within 41–43 days
and the tumor weights were similar (Additional file 18:
Figure S10H). No metastases were detected at necropsy
(data not shown). We noted that Vdac1−/− RAS MEF-
derived tumors showed bloody tumors with a soft tex-
ture while Wt RAS MEF-derived tumors had a harder
texture (data not shown) (Additional file 15: Figure
S11A). The level of HIF-1α and HIF-2α was higher in
the three tumors derived from Vdac1−/− RAS MEF than
in Wt RAS MEF (Fig. 6c). Compared to Wt RAS MEF-
derived tumors, there was a significance increase in the
number of CD31-positive vessels (Fig. 6d) and number of
vessels (Additional file 15: Figure S11B-C). Moreover, the
immunofluorescence to alpha-smooth muscle actin was
higher for Wt than for Vdac1−/− RAS MEF tumors
(Fig. 6e). Masson’s trichome staining showed a massive
leak of red blood cells from blood vessels into the tumor
tissue of the Vdac1−/− RAS MEF (Fig. 6f) and more hemo-
globine in the tumor (Additional file 15: Figure S11D),
suggesting that the leak came from partial vascular remod-
eling, probably coupled with enhanced permeability.
When comparing the non-transformed Vdac1−/− to Wt
MEF in the IPATM analysis for «Development of blood
vessels», three genes were highly induced, matrix
metalloproteinase-3 (Mmp3), platelet-derived growth fac-
tor β (Pdgfβ), and collagen type XVIII alpha 1 (Col18A1),
while one gene, thrombomodulin (Thbd), was highly re-
pressed. Evaluation of the level of the mRNA confirmed
the IPATM results with the exception of Pdgfβ (Fig. 6g).
From the IPATM analysis (Additional file 2: Table S1A-C,
Additional file 3: Table S2A-C), the inflammatory response
was central to loss of VDAC1. Moreover, as leakage may
be associated with ROS production, generating an inflam-
matory response, we investigated the expression of
pro-inflammatory genes. Increased expression of the
pro-inflammatory cytokines interleukine 8 (Il-8) and che-
mokine (C-X-C motif) ligand 5 (CxCl5) were detected in
Fig. 5 Knockout of Vdac1 maintains a basal level of apoptosis. a Wt and Vdac1−/− MEF were cultured for 3 days in normoxia (Nx) or hypoxia 1 %
O2 (Hx). The percentage cell mortality was measured by trypan blue exclusion. A p < 0.05 shows a tendency from the basal apoptosis of Wt MEF.
b Cells were stained with DAPI (blue) to highlight the nucleus and its morphology. Quantification of the percentage of blebbing in Wt and Vdac1−/−
MEF. At least 200 nuclei were counted blindly. c Wt (+) and Vdac1−/− (−) MEF were incubated in Nx or Hx for 72 h and cell lysates were analyzed by
immunoblotting for Bak, Bax, Mcl-1, Bcl-XL, Bcl-2, VDAC, and HKII. β-actin was used as a loading control. d Wt and Vdac1−/− MEF were incubated in Nx
or Hx for 72 h and challenged with staurosporin (STS) (1 μM) for 4 h. Apoptosis was evaluated from the level of caspase 3/7. A p < 0.001 and p < 0.0001
show significant differences. e Wt and Vdac1−/− MEF were cultured for 2 days and then treated for 3 days with staurosporine (STS) (1 μM), cisplatin (CIS)
(2 μg/ml), doxorubicin (DOXO) (4 μg/ml), or bleomycin (Bleo) (10 μg/ml). Cell viability was measured using an ADAM cell counter. A p < 0.02, p < 0.002,
and p < 0.005 show significant differences. f Radioresistance of Wt and Vdac1−/− MEF cultured for 24 h in Nx or Hx and treated with the indicated dose
of radiation. Cell growth was then evaluated with a clonogenic cell survival assay. X-axis: dose of X-radiation (Gy). Y-axis: surviving fraction. The mean ±
SEM is representative of two independent experiments carried out in duplicate. A p < 0.01 and p < 0.005 show significant differences
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noted that cyclin-dependent kinase inhibitor 2A (Cdkn2A)
(Fig. 1f, Additional file 6: Figure S1), a tumor suppressor
gene, was markedly inhibited, likely via HIF-1α in nor-
moxia and hypoxia in the absence of VDAC1. Theexpression level of Cdkn2A (Fig. 6i) was decreased likely
favoring the rapid growth of Vdac1−/− RAS MEF-derived
tumors. Wt RAS MEF-derived tumors showed a much
higher level of staining for VEGFA than Vdac1−/− RAS
MEF tumors, which correlated with the decrease in CD31-
Fig. 6 In vivo allograft tumor growth of RASV12-transformed MEF expressing (Wt RAS MEF) or not (Vdac1−/− RAS MEF) VDAC1. a Wt RAS (+) and
Vdac1−/− RAS (−) MEF were incubated in Nx for 24 h and cell lysates were analyzed by immunoblotting for RAS and VDAC. β-tubulin was used as
a control. b Allograft tumor growth of Wt RAS MEF and Vdac1−/− RAS MEF injected into one of the flanks of nod-scid mice. Five mice were studied per
condition. A p < 0.0000001 shows significant differences. c Wt RAS (tumors 1, 2, and 3) and Vdac1−/− RAS MEF-derived tumors (tumors 4, 5, and 6) cell
lysates were analyzed by immunoblotting for HIF-1α, HIF-2α, and VDAC. β-tubulin was used as a loading control. d Immunofluorescence of CD31 to
detect blood vessels in Wt RAS and Vdac1−/− RAS MEF-derived tumors. e Immunofluorescence of α-smooth muscle actin to visualize the structure of
blood vessels in Wt RAS and Vdac1−/− RAS MEF-derived tumors. f Representative images of Masson’s trichrome stained Wt RAS and Vdac1−/− RAS
MEF-derived tumors. Red staining indicates red blood cells. g Expression of the mRNA of Mmp3, Col18A1 (Endostatin) and Thbd in Wt RAS (Wt RAS
MEF) and Vdac1−/− RAS MEF-derived tumors (Vdac1−/− RAS MEF). h Expression of the pro-inflammatory cytokine mRNA of Il8 and Cxcl5 in Wt RAS (Wt
RAS MEF) and Vdac1−/− RAS MEF-derived tumors (Vdac1−/− RAS MEF). i Expression of the mRNA of Cdkn2a in Wt RAS (Wt RAS MEF) and Vdac1−/− RAS
MEF-derived tumors (Vdac1−/− RAS MEF)
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(Additional file 16: Figure S12). These results suggest a
strong impact of VDAC1 on tumor development, probably
through alterations in the inflammatory response as a result
of an abnormal vasculature due to HIF-1α stabilization and
ROS production.Discussion
Herein, we characterized the gene expression profile and
cellular phenotype of Vdac1-deficient MEF in normoxia
or hypoxia. Our results revealed important functions of
VDAC1, in cultured cells and in in vivo allograft tumors,
which were primarily driven by ROS and HIF-1.
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in normoxia and hypoxia were compared keeping in
mind that the other isoforms VDAC2 and VDAC3 may
compensate [24]. However, we did not detect the
VDAC2 protein, and the expression of VDAC3 protein
remained constant. When comparing Vdac1−/− to Wt
MEF, the largest difference in expression was noted in
normoxia, as HIF-1α and HIF-2α were already stabilized
by ROS in Vdac1−/− MEF. Therefore, the hypoxic effect
on gene expression was diminished in Vdac1−/− MEF.
The mRNAs affected by the loss of VDAC1 are involved
in cancer and metastasis, but also in fibrosis, neuromus-
cular disease and finally in the inflammatory response.
The role of VDAC1 in cancer has only just started to be
investigated [7, 8, 4]. The results of the present study re-
veal that the role of VDAC1 in cancer is connected to
modulation of energy and cell death, which are closely
interconnected. We noted a decrease in glycolysis in
Vdac1−/− MEF possibly due to the decrease in HKII ex-
pression. HKII has been shown to protect cancer cells
from entering apoptosis by blocking the interaction of
the pro-apoptotic protein Bax with VDAC1 [25]. Two
critical anti-apoptotic factors, Bcl-XL and Bcl-2, were
expressed in Vdac1−/− MEF. Bcl-XL has been shown to
critically regulate the opening of VDAC1 and to thus in-
fluence apoptosis, possibly through the permeability
transition pore complex V [26-29]. Interestingly, in
Vdac1−/− MEF, neither Bcl-XL nor Bcl-2, two critical
anti-apoptotic factors, were expressed. As Bcl-XL may
influence metabolism [30], it is tempting to hypothesize
that the absence of Bcl-XL, like HKII, may play a role in
the reduced capacity to produce energy of Vdac1−/−
MEF in normoxia. A decrease in expression of HKII
and Bcl-XL would certainly affect apoptosis. Indeed,
mitochondria-associated HKII has been shown to pro-
tect cancer cells from entering apoptosis by blocking the
interaction of the pro-apoptotic protein Bax with VDAC1
[25]. Moreover, a decrease in the pool of anti-apoptotic
proteins such as Bcl-XL or Bcl-2 will inevitably destabilize
the balance of anti-apoptotic/pro-apoptotic factors. We
observed a basal level of apoptosis (around 10 % cell
death), suggesting that VDAC1 is indispensable for mito-
chondrial cell death. This contrasts with data of a previous
study using the same MEF [31].
In hypoxia in Vdac1−/− MEF, we observed both enlarged
mitochondria with abundant cristae and mitochondria
similar to those in normoxia. The former may reflect the
improved proliferation, thus better bioenergetics of the
cells, and the later of mitochondria that had not or could
not adapt. However, one question remains: how do these
cells survive in normoxia with a low level of glycolysis and
respiration? Fatty acid alpha oxidation by Vdac1−/− MEF
could be a possible explanation. The deficiency in Vdac1
in both MEF and RAS-transformed MEF resulted in areduction in proliferation in normoxia. Examination of the
analytic technique for assessment of RNAi by similarity
(ATARiS) [32], a computational method to assess the ef-
fects of gene suppression on cell survival/proliferation, in
the Project Achilles database [33] supported this result. We
specifically focused on cell lines with K-Ras mutations. The
ATARiS gene-level score of dependency showed that
knockout of Vdac1 decreased proliferation, even in human
cancer cells driven by oncogenic K-Ras (Additional file 17:
Figure S13A). Based on these results, could Vdac1 be a
putative cancer driver gene in human cancer? The Can-
cer Genome Atlas (TCGA) data sets from 89 cancer
studies were analyzed for gene mutation, deletion, gain,
and amplification in the Vdac1 gene with cBioPortal
(http://www.cbioportal.org) [34, 35]. The alteration fre-
quency varied from 80 to 1 % depending on the type of
cancer. The Vdac1 gene was mainly heterologously lost
(light blue) and/or gained (pink). Homologous loss
(dark blue) and amplification (red) were also observed,
which suggested a putative role in development of hu-
man cancers (Additional file 17: Figure S13B). However,
Vdac1−/− MEF grew better than Wt MEF in hypoxia,
and ERK activation was required. Chan et al. showed
that ROS can participate in the degradation of DUSP6
[36]. Since ROS accumulated in Vdac1−/− MEF, due in
part to a decrease in GPX7 expression, DUSP6 was de-
graded in normoxia and hypoxia.
The data from Vdac1−/− RAS MEF tumors in mice
emphasized two major events: i) destructuration of
blood vessels and ii) inflammation. The increase in
endostatin, an inhibitor of angiogenesis that inhibits
endothelial cell proliferation, migration/invasion, and
tube formation, may explain the decrease in the number
of blood vessels in these tumors. Moreover, the low level
of VEGFA expression in the Vdac1−/− RAS MEF tumors
reinforced the implication of VDAC1 in vascular devel-
opment. This newly identified role of VDAC1 in modu-
lating the structure of blood vessels may explain why the
expected Mendelian ratio of 1:2:1 was not observed for
heterozygous mice (Vdac1+/−) [5]. Only 40 % of the ex-
pected number of Vdac1−/− mice survived and, using
timed matings, the fetal loss was determined to occur
between embryonic day 10.5 and 11.5, a time during
which blood vessel formation occurs. We speculate that
60 % of the Vdac1−/− mice may develop dysfunctional
blood vessels during embryogenesis. Why the other 40 %
survive and show no obvious outward signs of deficiency
remains obscure. The Vdac1−/− RAS MEF tumors showed
less blood vessels than Wt tumors and exhibited an inflam-
matory response that may result from infiltration of red
blood cells (RBCs) through permeabilization of the
remaining blood vessels. RBCs could serve as a potential
source of ROS since they contain a large pool of O2
that is autoxidized in a hypoxic microenvironment,
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responses to tissue damage due to ROS is production
of IL-8, a pro-inflammatory cytokine often associated
with advanced stage cancer and with poor prognosis.
RBCs can also bind inflammatory mediators such as IL-8.
The mRNA level of Il-8 and Cxcl5 were markedly elevated
in Vdac1−/− RAS MEF, which supports the hypothesis ofFig. 7 Schematic representation of the impact of Vdac1 knockout (Vdac1−/
in vivo (b). a In normoxia (Nx), the knockout of Vdac1 was associated with
(cytochrome C leakage). In hypoxia (Hx), the knockout of Vdac1 maintained
DUSP6 while allowing slight activation of P-ERK. Activated P-ERK effected t
b Through production of ROS, which stabilizes HIF-1α, a cascade of events
and induced an inflammatory response. This cascade will then lead to a pro-tum
CDKN2A: cyclin-dependent kinase inhibitor 2A; CxCL5: chemokine (C-X-C motif)an enhanced inflammatory response. Finally, it has been
shown that RBCs may induce the secretion of matrix
metalloproteinases such as mmp-3 by fibroblasts [38],
which impacts on tissue remodeling. Thrombomodulin,
a protein that maintains vascular homeostasis via its
anti-inflammatory properties [39], was not expressed in
the Vdac1−/− RAS MEF, so the pro-inflammatory−) on proliferation and cell death of MEF in vitro (a) and tumor growth
production of ROS that reduced proliferation and increased apoptosis
the production of ROS but the effect was offset by inhibition of
he activity of COX7A1 and COX4-2, while promoting proliferation.
induced (+) or repressed (−) processes that destabilized blood vessels
oral response. αSMA: alpha-smooth muscle actin; THBD: thrombomodulin;
ligand 5; IL8: interlukin 8; MMP3: matrix metallopeptidase 3
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leading to tumor development was accompanied by a
notable decrease in the mRNA level of Cdkn2A, a
tumor suppressor gene.
While we observed more rapid tumor growth of
Vdac1−/− RAS MEF compared to Wt RAS MEF, a study
using A549 cells (human lung adenocarcinoma epithelial
cells) reported that the silencing of Vdac1 expression
with siRNA inhibited cancer cell proliferation and tumor
growth in vivo [40]. However, we used a mouse/mouse
system (tumor/host) while Arif et al. used a human/
mouse system (tumor/host). In addition, we used MEF
rather than lung cancer cells. Finally and most import-
antly, our system was a total knockout of Vdac1 and not
on partial and temporary silencing as for siRNA. Is
angiogenesis induced in the same way in these tumors?
We suggest that the Vdac1−/− RAS MEF adapted and
offset an imbalance in some metabolic, angiogenic, or
inflammatory processes to proliferate.
Conclusions
Our study demonstrates that VDAC1 is not just a pore
that allows passage of metabolites; it is a major mito-
chondrial protein that controls crucial processes in-
volved in vital functions such as metabolism and cell
death (Fig. 7). This study provides a rationale for investi-
gating VDAC1 as a therapeutic target in both normoxic
and hypoxic tissues with tumor characteristics.
Additional files
Additional file 1: Supplemental Materials and Methods.
Additional file 2: Table S1. Main biological functions associated with
the alterations of Vdac1−/− MEF compared to Wt MEF (Wt) in normoxia
(Nx) or hypoxia (Hx). Significant categories of (A) diseases and functions,
(B) canonical pathways, and (C) upstream regulators associated with the
comparison of wild-type (Wt) and Vdac1−/− MEF in Nx or Hx using IPATM.
Activation z-score (cut-off = 2) or –log10 p value (cut-off = 2) are represented.
Additional file 3: Table S2. Main biological functions associated with
the comparison of hypoxic and normoxic conditions in Wt MEF or Vdac1−/−
MEF. Significant categories of (A) diseases and functions, (B) canonical
pathways, and (C) upstream regulators associated with the comparison of
Normoxia (Nx) and hypoxia (Hx) in wild-type (Wt) or Vdac1−/− MEF in using
IPATM. Activation z-score (cut-off = 2) or –log10 p value (cut-off = 2) are
represented.
Additional file 4: Table S3. Mus musculus dual specificity phosphatase
(DUSP) mRNA levels associated with the comparison of hypoxic and
normoxic conditions in Wt MEF or Vdac1−/− MEF.
Additional file 5: Table S4. Mus musculus superoxide dismutase (Sod),
glutathione peroxidase (GPX), and catalase (Cat) mRNA levels associated
with the comparison of hypoxic and normoxic conditions in Wt MEF or
Vdac1−/− MEF.
Additional file 6: Figure S1. HIF-1α signaling pathway in hypoxic
Vdac1−/− MEF vs Wt MEF. Red and green color codes for up- and down-
regulation, respectively.
Additional file 7: Figure S2. Perturbations in OXPHOS in Vdac1−/− MEF.
Ingenuity pathway analysis of the OXPHOX in Vdac1−/− vs Wt MEF in Nx
and Hx. Green color codes for down-regulation.Additional file 8: Figure S3. Cytochrome oxidase expression: (A)
Immunofluorescence to COX4-2 in Wt and Vdac1−/− MEF in Nx for 72 h
and (B) COX4-2 in Wt and Vdac1−/− MEF in Hx for 72 h in the absence
(Ctl) or presence of the MEK inhibitor (PD184352).
Additional file 9: Figure S4. Reactive oxygen species status of Wt and
Vdac1−/− MEF. (A) Mitochondrial hydrogen peroxide production. (B)
Immunoblotting for SOD1, SOD2, and SOD3 of Wt (+) and Vdac1−/− (−)
MEF incubated in normoxia or hypoxia for 72 h. β-tubulin was used as a
loading control.
Additional file 10: Figure S5. Glutathione peroxidase expression and
the effect of ebselen. (A) Immunofluorescence to GPX7 in Wt and Vdac1−/−
MEF in Nx or Hx for 72 h. (B) Immunoblotting for HIF-1α of Wt and Vdac1−/−
MEF in the absence or presence of ebselen in normoxia. (C) Proliferation of
Wt and Vdac1−/− MEF in the absence or presence of ebselen in normoxia.
(D) Viability of Wt and Vdac1−/− MEF in the absence or presence of ebselen
in normoxia.
Additional file 11: Figure S6. Changes in metabolic pathways in
Vdac1−/− vs Wt MEF. Ingenuity pathway analysis of the metabolic activity
of Vdac1−/− vs Wt MEF in (A) normoxia and (B) hypoxia. Red color code
for up- regulation.
Additional file 12: Figure S7. Glucose and glutamine metabolism.
(A) Wt and Vdac1−/− MEF were cultured for 2 days in Nx or Hx in the
presence of 2-deoxy-D-glucose (2DG, 1 μM) or without glucose (−Gluc).
The cell number was measured on a Beckman Coulter apparatus (squares).
The percentage of cell mortality was measured by trypan blue exclusion
(black dots). The mean ± SEM is representative of two independent
experiments carried out in duplicate. (B) The glutamate concentration in the
media of Wt and Vdac1−/− MEF cultured in normoxia (Nx) or hypoxia 1 % O2
(Hx) was measured at day 7 using a YSI 2700 apparatus. Vdac1−/− MEF
convert little or no glutamine into glutamate compared to Wt MEF.
Additional file 13: Figure S8. Knockout of Vdac1 significantly disrupted
apoptosis. Immunofluorescence to cytochrome C and DAPI in Wt and
Vdac1−/− MEF in Nx.
Additional file 14: Figure S9. Autophagy was detected in Vdac1−/−
MEF. (A) Representative images of electron micrographs of Wt and Vdac1−/−
MEF incubated in normoxia (Nx) for 24 h. Vdac1−/− MEF showed
autophagosomes with double membranes (arrow). (B) Wt and Vdac1−/−
MEF lysates were analyzed in the absence (−) or presence of chloroquine
(CQ) by immunoblotting to LC3. ARD1 was used as a loading control. The
ratio of LC3-II/ARD1 was measured.
Additional file 15: Figure S11. Red blood cells are present in Vdac1−/−
RAS MEF tumor tissue. (A) 20 mg of tumor tissue derived from Wt (1, 2, and
3) and Vdac1−/− RAS MEF (4, 5, and 6) tumors were resuspended in RLT
buffer before DNA/RNA/protein extraction. (B) Quantification of the number
of blood vessels/microscopic field of CD31-positive vessels ± SEM of tumor
tissue derived from Wt RAS (1, 2, and 3) and Vdac1−/− RAS MEF (4, 5, and 6).
(C) Average of the quantification of CD31-positive vessels ± SEM per micro-
scopic field in Wt RAS MEF-derived tumors (Wt RAS MEF) and Vdac1−/− RAS
MEF-derived tumors (Vdac1−/− RAS MEF). Statistical significance, p < 0.0001.
(D) Immunofluorescence to hemoglobin (Hgb) in Vdac1−/− RAS MEF.
Additional file 16: Figure S12. Immunohistochemical staining for
VEGFA of tumor sections. (A) Negative control using secondary antibody
only on Wt RAS MEFs. (B) VEGFA immunodetection in sections of Wt and
Vdac1−/− RAS MEF-derived tumor using 4X (top panels), 20X (middle
panels), and 40X (bottom panels) magnification.
Additional file 17: Figure S13. VDAC1 expression in human tissues
and cancers. (A) Heatmaps run from blue (low values, more dependency/
essentiality) to white to red (high values, less dependency/essentiality).
ATARiS gene-level data are median centered and therefore relative within
the particular gene that is being viewed. (B) The Cancer Genome Atlas
(TCGA) data sets of 89 cancer studies analyzed for mutation, deletion,
gain, and amplification in the Vdac1 gene with cBioPortal.
Additional file 18: Figure S10. Characterization of RASV12 transformed
MEF expressing (WT RAS MEF) or not (Vdac1−/− RAS MEF) Vdac1. (A)
Characterization of the growth of Wt and Vdac1−/− RAS MEF incubated in
Nx or Hx for the indicated number of days. The mean ± SEM is representative
of four independent experiments carried out in duplicate. A p < 0.00001
Brahimi-Horn et al. Cancer & Metabolism  (2015) 3:8 Page 17 of 18shows significant difference from the normoxia for Vdac1−/− RAS MEF. (B)
Representative phase contrast photographs of Wt and Vdac1−/− RAS MEF
incubated in Nx for 72 h. Scale bars represent X μm. (C) Relative migration of
Wt and Vdac1−/− RAS MEF in Nx as evaluated in a xCELLigence system. The
mean ± SEM is representative of two independent experiments carried
out in quadruplicate. (D) The extracellular acidification rate (ECAR) in Nx
of Wt and Vdac1−/− RAS MEF was evaluated with a Seahorse XF
bioenergetic system. Glucose (Glu 10 mM) and oligomycin (Oligo 1 μM)
were injected at the indicated times. (E) The oxygen consumption rate
(OCR) in Nx for Wt and Vdac1−/− RAS MEF was measured in real time
with a Seahorse XF. Glucose (Glu 10 mM), oligomycin (Oligo 1 μM),
carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP 1 μM), and
Rotenone/Antimycine A (Rot/AA, 1 μM/1 μM) were injected at the
indicated times. The mean ± SEM is representative of three independent
experiments carried out in quadruplicate. (F) Radioresistance of Wt and
Vdac1−/− RAS MEF cultured for 24 h in Nx or Hx and treated with the
indicated dose of radiation. Cell growth was then evaluated with a
clonogenic cell survival assay. X-axis: dose of X-radiation (Gy). Y-axis:
surviving fraction. The mean ± SEM is representative of two independent
experiments carried out in duplicate. (G) Soft agar assay of Wt and Vdac1−/−
RAS MEF. (H) Tumor weight of Wt (Wt RAS MEF) and Vdac1−/− RAS MEF-
derived tumors (Vdac1−/− RAS MEF).
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